Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer has an extremely poor prognosis with a 5-year survival rate of less than
5%. About 25% of patients have the opportunity for radically surgical resection when
diagnosis. However, the recurrence rate is up to 85% within 2 years. Data from clinical
trials indicated that gemcitabine-based adjuvant chemotherapy reduced recurrence and enhanced
overall survival for patients who have undergone surgery to remove their tumor.
Nab-paclitaxel could enhance the intratumoral concentration of gemcitabine; recent studies
showed that nab-paclitaxel plus gemcitabine significantly improved progression-free survival
and overall survival of metastatic pancreatic cancer patients. The present study is intended
to investigate the activity and safety of the combination of gemcitabine and nab-paclitaxel
as adjuvant chemotherapy in treating patients with pancreatic cancer after curative
resection.